Gagelmann et al reported a clinical-molecular scoring system for evaluating a patient with myelofibrosis undergoing stem cell transplantation. The authors are from University Medical Center Hamburg-Eppendorf, University Hospital Essen, Hopital Saint-Louis and Hannover Medical School.
Patient selection: myelofibrosis, undergoing allogeneic stem cell transplantation
Parameters:
(1) age in years
(2) Karnofsky performance status
(3) platelet count in 10^9/L
(4) leukocyte count before transplantation in 10^9/L
(5) HLA match for donor
(6) ASXL1 mutation
(7) non-CALR/MPL driver mutation
Parameter
Finding
Points
age in years
< 57 years
0
>= 57 years
1
Karnofsky status
>= 90%
0
< 90%
1
platelet count
>= 150 * 10^9/L
0
< 150 * 10^9/L
1
leukocyte count
<= 25 * 10^9/L
0
> 25 * 10^9/L
1
HLA match for donor
mismatched, unrelated
2
other
0
ASXL1 mutation
no
0
yes
1
non-CALR/MPL driver mutation
no
0
yes
2
total score =
= SUM(points for all of the parameters)
Interpretation:
• minimum score: 0
• maximum score: 9
Score
Risk Group
5-Year Survival
0 to 2
low
83%
3 or 4
intermediate
64%
5
high
37%
>= 6
very high
22%
Performance:
• The area under the ROC curve is 0.72.
Continue Reading
